Please use this identifier to cite or link to this item:
Título : HPV Vaccination Recommendation Practices among Adolescent Health Care Providers in 5 Countries
Autor : Kundu, Debanjali 
Peris, Merce 
Morgan, Karen 
Smith, Jennifer S 
Ramos, Silvina 
Kim, Chan Joo 
Topazian, Hillary M 
Richter, Karin L 
Peebles, Kathryn 
Brewer, Noel T 
Palabras clave : VACUNA CONTRA HPV;Adolescentes;Neoplasias del Cuello Uterino;Vacunas;Conocimientos, Actitudes y Práctica en Salud;Argentina;Sudáfrica;Malasia;República de Corea;España
Fecha de publicación : Dec-2018
Editorial : 1873-4332
Resumen : STUDY OBJECTIVE: To assess adolescent health care providers' recommendations for, and attitudes towards human papillomavirus (HPV) vaccination in 5 countries. DESIGN: In-depth interviews of adolescent health care providers, 2013-2014. SETTING: Five countries where HPV vaccination is at various stages of implementation into national programs: Argentina, Malaysia, South Africa, South Korea, and Spain. PARTICIPANTS: Adolescent health care providers (N = 151) who had administered or overseen provision of adolescent vaccinations (N = Argentina: 30, Malaysia: 30, South Africa: 31, South Korea: 30, Spain: 30). MAIN OUTCOME MEASURES: Frequency of HPV vaccination recommendation, reasons providers do not always recommend the vaccine and facilitators to doing so, comfort level with recommending the vaccine, reasons for any discomfort, and positive and negative aspects of HPV vaccination. RESULTS: Over half of providers 82/151 (54%) recommend HPV vaccination always or most of the time (range: 20% in Malaysia to 90% in Argentina). Most providers 112/151 (74%) said they were comfortable recommending HPV vaccination, although South Korea was an outlier 10/30 (33%). Providers cited protection against cervical cancer 124/151 (83%) and genital warts 56/151 (37%) as benefits of HPV vaccination. When asked about the problems with HPV vaccination, providers mentioned high cost 75/151 (50% overall; range: 26% in South Africa to 77% in South Korea) and vaccination safety 28/151 (19%; range: 7% in South Africa to 33% in Spain). Free, low-cost, or publicly available vaccination 59/151 (39%), and additional data on vaccination safety 52/151 (34%) and efficacy 43/151 (28%) were the most commonly cited facilitators of health provider vaccination recommendation. CONCLUSION: Interventions to increase HPV vaccination should consider a country's specific provider concerns, such as reducing cost and providing information on vaccination safety and efficacy.
DOI: 1873-4332
Appears in Collections:Artículos en publicaciones periódicas

Show full item record

Page view(s)

checked on Jan 25, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.